A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed LymphomaPeter Martin, Leandro Cerchietti, Nancy L. Bartlett et al.|Blood|2017Cited by 8
A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma.Gopa Iyer, Matt D. Galsky, Benjamin Garmezy et al.|Journal of Clinical Oncology|2024Cited by 5